Nephropathie bei Diabetes

Ludwig Merker; Thomas Ebert; Erwin Schleicher; Martina Guthoff; Berend Isermann

doi:10.1055/a-2076-0202

Diabetologie und Stoffwechsel, Table of Contents

Diabetologie und Stoffwechsel 2023; 18(S 02): S342-S347
DOI: 10.1055/a-2076-0202

DDG-Praxisempfehlung

Nephropathie bei Diabetes

Authors

Ludwig Merker

¹Diabetologie im MVZ am Park Ville d’Eu, Haan, Deutschland
Thomas Ebert

²Medizinische Klinik III – Klinik und Poliklinik für Endokrinologie, Nephrologie, Rheumatologie, Universitätsklinikum Leipzig, Leipzig, Deutschland
Erwin Schleicher

³Institut für Klinische Chemie und Pathobiochemie – Zentrallabor; Universitätsklinikum Tübingen, Tübingen, Deutschland
Martina Guthoff

⁴Medizinische Klinik IV, Diabetologie, Endokrinologie, Nephrologie, Universitätsklinikum Tübingen, Tübingen, Deutschland
Berend Isermann

⁵Institut für Laboratoriumsmedizin, Klinische Chemie und Molekulare Diagnostik, Universitätsklinikum Leipzig, Leipzig, Deutschland

Abstract

Full Text

References

Literatur
1 Mogensen CE. Introduction: Diabetes mellitus and the kidney. Kidney Int 1982; 21: 673-675
2 Kidney Disease: Improving Global Outcomes (KDIGO). CKD Work Group KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Supplements 2013; 3: 1-150 . Im Internet (Stand: 25.07.2023): https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf
3 de Boer IH, Khunti K, Sadusky T. et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 2022; 45: 3075-3090
4 Rossing P, Caramori ML, Chan JCN. et al. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2022; 102: S1-S127
5 Williams B, Mancia G, Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur. Heart J 2018; 39: 3021-3104
6 Cheung AK, Chang TI, Cushman WC. et al. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int 2021; 99: S1-S87
7 Davies MJ, Aroda VR, Collins BS. et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2022; 45: 2753-2786
8 Landgraf R, Aberle J, Birkenfeld AL. et al. Therapie des Typ-2-Diabetes. Diabetol Stoffwechs 2022; 17 (Suppl. 02) S159-S204
9 Bally L, Gubler P, Thabit H. et al. Fully closed-loop insulin delivery improves glucose control of inpatients with type 2 diabetes receiving hemodialysis. Kidney Int 2019; 96: 593-596
10 Boughton CK, Tripyla A, Hartnell S. et al. Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial. Nat Med 2021; 27: 1471-1476
11 Mach F, Baigent C, Catapano AL. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111-188
12 Sattar N, Lee MMY, Kristensen SL. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 2021; 9: 653-662
13 Baigent C, Emberson JR. et al. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. The Lancet 2022; 400: 1788-1801
14 Perkovic V, Jardine MJ, Neal B. et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380: 2295-2306
15 Heerspink HJL, Stefánsson BV, Correa-Rotter R. et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020; 383: 1436-1446
16 The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2023; 388: 117-127
17 Agarwal R, Filippatos G, Pitt B. et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 2022; 43: 474-484